Know Cancer

forgot password

A Prospective, Multicenter Phase I/II Safety and Tolerability Study of Unilateral Vascular-Targeted Photodynamic Therapy Using WST11 in Patients With Localized Prostate Cancer

Phase 1/Phase 2
18 Years
Not Enrolling
Prostate Cancer

Thank you

Trial Information

A Prospective, Multicenter Phase I/II Safety and Tolerability Study of Unilateral Vascular-Targeted Photodynamic Therapy Using WST11 in Patients With Localized Prostate Cancer

This study is designed as a multicenter, phase I/II, prospective, open-labeled, single
intravenous (IV) dose, clinical trial in patients with localized prostate cancer.

The study population will be men who have been offered curative therapy (radical
prostatectomy; cryotherapy; brachytherapy; EBRT), and refused. Patients must have already
had a previous biopsy showing a histologically proven carcinoma of the prostate. The
identification and the location of the tumor will be done using both dynamic contrast MRI
and biopsy.

Only unilateral treatment with WST11-medicated VTP will be performed during the study.
Treatment will consist of a single, 10 minute, IV administration of WST11 at doses of
2mg/kg, 4 mg/kg or 6 mg/kg, followed by either light activation delivered through
transperineal interstitial optical fibers for 20 minutes using 753 nm laser light at
escalating fixed energy doses of 200 J/cm or 300 J/cm by escalating power at each energy to
167 mW/cm or 250 mW/cm respectively. A brachytherapy-like template is used for the placement
of the transparent implant catheters which are positioned in the prostate under transrectal
ultrasound image guidance. The illumination fiber(s) are then inserted into the implant

If the safety profile for a given WST11 and light dose is acceptable, additional patients
(up to 3) may be treated with multiple fibers at that WST11 treatment dose.

For cases where the Month 6 biopsy is positive, the patient will be offered the opportunity
to be retreated with WST11

Inclusion Criteria:

- At least 18 years of age

- Diagnosed with localized, prostate cancer and who have been offered curative therapy
(radical prostatectomy; cryotherapy; brachytherapy; EBRT), and refused

- Localized prostate cancer stage T1C up to T2A based on biopsy performed at least 6
weeks prior to enrollment

- Gleason score ≤ 3+3 with ≤50% of sampled cores positive, and each positive core
having a tumour length of ≤5 mm

- PSA < 10 ng/mL

- No prior treatment for prostate cancer

- Signed Informed Consent Form

Exclusion Criteria:

- Any condition or history of illness or surgery that, in the opinion of the
investigator and/or the Sponsor, might confound the results of the study or pose
additional risks to the patient.

- All patients whose current pre-operative cardiac evaluation does not show their
fitness for a procedure requiring general anesthesia;

- Patients with a prior history of viral or alcoholic hepatitis, and other patients
felt to be at risk for hepatotoxicity including concomitant use of potentially
hepatotoxic medications or dietary supplements;

- Patients with a history of inflammatory bowel disease or other factors which may
increase the risk of fistula formation;

- Patients who have received any hormonal manipulation (excluding 5-alpha reductase
inhibitors) or androgen supplements within the previous 6 months;

- Patients previously treated by radiation therapy (external therapy or brachytherapy)
or chemotherapy or any therapy for prostate cancer;

- Patients who have received or are receiving chemotherapy for prostate carcinoma or
other significant cancer;

- Patients who have undergone previous TURP (trans-urethral resection of the prostate);

- Patients with a history of urethral stricture disease

- Patients with a history of acute urinary retention

- Patients who are currently (within 10 days before the treatment procedure) receiving
any medications having potential photosensitizing effects (e.g. tetracyclines,
sulfonamides, phenothiazines, sulfonylurea hypoglycemic agents, thiazide diuretics
and griseofulvin)

- Patients who are currently receiving anticoagulant drugs (within 10 days before the
treatment procedure) (e.g.: coumadin, warfarin)

- Patient who stopped long term treatment of acetylsalicylic acid (aspirin) or other
anti platelets agents within 10 days prior to the treatment procedure;

- Patient suspected of Disseminated Intravascular Coagulation (DIC) as defined by the
presence of three out of the five following criteria: platelets decrease, increase of
PT, increase of aPTT, fibrinogen decrease, D-Dimer increase; from the normal
laboratory ranges;

- Patient with a history of vasculitis or collagen vascular disease;

- History of non compliance with medical therapy and medical recommendations or an
unwillingness or inability to complete patient self-administered questionnaires;

- Participation in a clinical study or receipt of an investigational treatment within
the past 3 months;

- A history of porphyria;

- A history of sun hypersensitivity or photosensitive dermatitis;

- Renal disorders (blood creatinine > 1.5 x ULN) or known post mictional residue >

- Hepatic disorders (transaminases > ULN, bilirubin > ULN, GGT > ULN). In case of
slight abnormalities, another exam could be performed. If the results are within
normal ranges, then the patient can be included;

- Hematological disorders (white cells < 2500/mm3, neutrophils < 1500/mm3, platelets, <
140.000/mm3, Hb ≤ 10 g/dL);

- Patients with contra-indication to MRI (such as pace maker, metal prosthesis, etc.).

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To define the study drug and light dosage combination to achieve negative biopsy in the treated lobe.

Outcome Time Frame:

Month 6

Safety Issue:


Principal Investigator

Samir Taneja, Professor

Investigator Role:

Principal Investigator

Investigator Affiliation:

Department of Urology, New York University Cancer Institute


United States: Food and Drug Administration

Study ID:

CLIN901 PCM202



Start Date:

July 2009

Completion Date:

August 2012

Related Keywords:

  • Prostate Cancer
  • Prostatic disease
  • genital neoplasm, male
  • Urogenital neoplasm
  • Genital disease
  • male
  • Male urogenital disease
  • Neoplasms
  • Neoplasm by site
  • prostatic neoplasm
  • Carcinoma
  • Prostatic Neoplasms



Memorial Sloan-Kettering Cancer Center New York, New York  10021
NYU Urology Associates New York, New York  10016
UCLA - Jonsson Comprehensive Cancer Center Los Angeles, California  90095
Midtown Urology & Midtown Urology Surgical Center Atlanta, Georgia  30308
Washington University School of Medicine- Barnes-Jewish Hospital St. Louis, Missouri  63110